Fixed ratio combination of basal insulin and GLP-1 receptor agonist
Insulin degludec with liraglutide injection
IDEGLIRA_SC
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.18 (-1.45 to -0.89) | 0.80 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.82 (-2.04 to 0.48) | 0.76 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Insulin glargine | MD -0.25 (-1.33 to 0.77) | 0.65 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 3.15 (-1.90 to 8.87) | 0.17 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 1.09 (-0.25 to 2.40) | 0.36 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Insulin glargine | MD -1.97 (-6.93 to 3.01) | 0.62 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 64 to 130 (target week 104) | Insulin glargine | MD -1.80 (-6.66 to 3.34) | 0.63 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Semaglutide injection | OR 1.20 (0.31 to 6.00) | 0.88 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 16.43 (4.86 to 40.82) | 0.94 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Insulin glargine | OR 1.78 (0.53 to 5.13) | 0.72 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.74 (0.08 to 8.62) | 0.31 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.77 (1.24 to 5.74) | 0.22 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.56 (-4.78 to -0.31) | 0.64 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 2.29 (-2.64 to 8.31) | 0.30 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 64 to 130 (target week 104) | Insulin glargine | MD -0.29 (-11.87 to 11.93) | 0.48 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD -0.58 (-4.23 to 2.85) | 0.26 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.86 (0.61 to 1.17) | 0.62 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.61 (0.14 to 3.07) | 0.72 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.24 (0.75 to 2.05) | 0.56 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.61 (0.54 to 5.16) | 0.54 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.25 (0.87 to 1.84) | 0.54 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.28 (0.67 to 2.46) | 0.51 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.24 (0.02 to 2.29) | 0.68 |
Trials
- NCT05767255Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue2022 · 65 randomized · 4 weeks
- DUAL™ I ChinaA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)2017 · 720 randomized · 26 weeks
- DUAL™ II ChinaA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other OAD2017 · 453 randomized · 26 weeks
- DUALTM IXA Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus. DUALTM IX - Add-on to SGLT2i2016 · 420 randomized · 26 weeks
- DUAL™ II JapanA Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs2016 · 210 randomized · 26 weeks
- DUAL™ VIIIA Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus2016 · 1,012 randomized · 104 weeks
- NCT02420262A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus2015 · 506 randomized · 26 weeks
- DUAL™ I JapanA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus2015 · 819 randomized · 52 weeks
- DUAL™ VA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V - Basal Insulin Switch)2013 · 557 randomized · 26 weeks
- DUAL™IVThe Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy2012 · 435 randomized · 26 weeks
- DUAL™ IIA 26-week Randomised, Parallel Two-arm, Double-blind, Multi-centre, Multinational, Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide With Insulin Degludec in Subjects With Type 2 Diabetes2011 · 413 randomized · 26 weeks